BioCrea is the first-in-class CNS discovery specialist validated through pharma partnerships.

BioCrea delivers first- and best-in-class CNS drug candidates. Early proof-of-concept, project value, risk awareness and patient-based data drive our decision making processes, which we apply to our drug discovery and development.

BioCrea has proven expertise in diseases such as Depression, Huntington’s disease, Epilepsy, Autism and Amyotrophic lateral sclerosis (ALS, Lou Gehrig’s Disease) in which current treatments are ineffective. Through an innovative discovery and multi-parameter optimization process we have a high potential to efficiently deliver effective preclinical drug candidates. 

BioCrea’s approach to drug discovery and development is validated by previous partnerships with companies that include Boehringer Ingelheim, Pfizer, Wyeth and GlaxoSmithKline.